DYN Dyne Therapeutics

Dyne Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference

Dyne Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- . (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that Joshua Brumm, president and chief executive officer, and Romesh Subramanian, Ph.D., chief scientific officer, are scheduled to present at the virtual 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 10:00 a.m. ET.

A live webcast will be available in the Investors & Media section of Dyne’s website at and a replay will be accessible for 90 days following the presentation.

About Dyne Therapeutics

Dyne Therapeutics is building a leading muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. The Company utilizes its proprietary FORCE™ platform to overcome the current limitations of muscle tissue delivery with modern oligonucleotide therapeutic candidates. Dyne is developing a broad portfolio of therapeutics for muscle diseases, including programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit , and follow us on ,  and .

Contact:

Dyne Therapeutics

Amy Reilly



857-341-1203



EN
05/01/2021

Underlying

DYNDyne Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Dyne Therapeutics

 PRESS RELEASE
Free
DYN Dyne Therapeuti...

Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-...

Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1) - HARMONIA trial will assess multi-system efficacy, safety and tolerability of z-basivarsen in DM1 - - 48-week trial will enroll approximately 150 individuals, and first sites are now open for enrollment - - Primary endpoint is the five times sit to stand (5xSTS) test; secondary and exploratory endpoints will assess muscle function, CNS manifestations, and patient- and clinician-reported outcomes - - HARMONIA trial design and protocol aligned with FDA; trial intended to ser...

March 8, 2026 1 EN
 PRESS RELEASE
Free
DYN Dyne Therapeuti...

Dyne Therapeutics Announces New Positive Cardiopulmonary Results from ...

Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) - New analyses out to 24-months showed improvement in heart and lung function compared to expected declines in DMD natural history - - Data expand on previously reported results demonstrating that z-rostudirsen treatment led to sustained functional improvement across multiple clinical measures - WALTHAM, Mass., March 08, 2026 (GLOBE NEWSWIRE) -- . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people livin...

March 8, 2026 1 EN
 PRESS RELEASE
Free
DYN Dyne Therapeuti...

Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial ...

Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights - Planned submission for U.S. Accelerated Approval of z-rostudirsen on track for Q2 2026; potential launch in Q1 2027 - - Positive topline results reported from Phase 1/2 DELIVER trial of z-rostudirsen in exon 51 skip amenable Duchenne muscular dystrophy (DMD); additional long-term data to be presented at MDA - - Completion of enrollment in registrational expansion cohort of Phase 1/2 ACHIEVE trial of z-basivarsen in myotonic dystrophy type 1 (DM1) expected in Q2 2026; Phase 3 tria...

March 2, 2026 1 EN
 PRESS RELEASE
Free
DYN Dyne Therapeuti...

Dyne Therapeutics to Participate in Upcoming Investor Conferences

Dyne Therapeutics to Participate in Upcoming Investor Conferences WALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to participate in the following upcoming investor conferences: TD Cowen 46th Annual Health Care Conference, fireside chat on Wednesday, March 4, 2026 at 11:50 a.m. ET in Boston, MA2026 Jefferies Biotech on the Beach Summit, hosting meetings on Tuesday, March 10 and Wednesday, Mar...

February 25, 2026 1 EN
 PRESS RELEASE
Free
DYN Dyne Therapeuti...

Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscula...

Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific Conference - Late-breaking poster to feature new positive cardiopulmonary function results from the DELIVER trial of z-rostudirsen in DMD - - Oral presentation on Phase 3 trial design for z-basivarsen in DM1 - - Five total presentations across three neuromuscular diseases demonstrate strength of Dyne’s pipeline based on clinically-validated FORCE™ platform - WALTHAM, Mass., Feb. 22, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: DYN), a clinical-stage company focused on delivering fun...

February 22, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch